SCHEMBL2332178

SCHEMBL2332178

Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc(C)c1NC(=O)c1cccc(NC(=O)c2cccnc2F)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.48
BRAF P15056 3/20 0.48
KDR P35968 4/20 0.46
MAPK14 Q16539 4/20 0.46
KIT P10721 3/20 0.46
TRPV1 Q8NER1 1/20 0.46
EPHX2 P34913 1/20 0.45
KCNK3 O14649 3/20 0.44
KCNK9 Q9NPC2 3/20 0.44
PTGES O14684 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
LCK P06239 4/20 0.44
BTK Q06187 3/20 0.44
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12348587 0.91 CSF1R (0.48) CSF1RBRAFKDRMAPK14KIT
SCHEMBL1819735 0.89 KMT2A (0.55) CSF1RBRAFKDRMAPK14KIT
SCHEMBL2105409 0.86 MEN1 (0.58) KCNK3KCNK9RXFP1MEN1HTT
SCHEMBL2261615 0.85 BRAF (0.44) CSF1RBRAFKDRMAPK14KIT
SCHEMBL22212760 0.85 BRAF (0.44) CSF1RBRAFKDRMAPK14KIT
SCHEMBL1821577 0.83 KCNK3 (0.58) BRAFKCNK3KCNK9MEN1HTT
SCHEMBL2103913 0.83 KCNK3 (0.57) KCNK3KCNK9MEN1HTTRAB9A
SCHEMBL4969614 0.83 KMT2A (0.54) RXFP1MEN1HTTKMT2A
SCHEMBL2261736 0.83 KCNK3 (0.60) KCNK3KCNK9PTGESRXFP1MEN1
SCHEMBL2260386 0.82 MEN1 (0.56) KCNK3KCNK9MEN1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 CSF1R 4882/4885BRAF 1064/4885KDR 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.